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1. Introduction 
Accumulating evidence suggests that alterations of neuron-astroglia interactions are associated 
with development of neurodegenerative diseases (Barres, 2008; Ricci et al., 2009; Verkhratsky 
et al., 2010). Astrocytes contribute to a variety of functions of neurons, including synapse 
formation and plasticity, energetic and redox metabolism, and synaptic homeostasis of 
neurotransmitters and ions (Bolton & Eroglu, 2009; Nimmerjahn, 2009; Salmina, 2009; 
Verkhratsky, 2010; Wang & Bordey, 2008). It is well known that astrocytes play important 
role in supporting energy production in neurons. Astrocytes produce lactate which is 
actively taken up by active neurons. They utilize lactate as an alternative energy fuel. In 
turn, neuronal activation results in glutamate-stimulated glycolysis in astroglial cells. Thus, 
neuron-astrocyte metabolic coupling provides tight interactions between the activated 
neuronal cells consuming lactate and lactate-producing astrocytes. Remodeling of astrocytes 
is required for adequate synapse turnover in the brain, and astrocytes or the closely related 
radial glial cells possess all the attributes of a neural stem cells, thereby playing a key role in 
neurogenesis (Steindler & Laywell, 2003; Theodosis et al., 2006). 
Functional relationship between neurons, glial cells, and vascular cells within so-called 
neurovascular unit is very important in the context of pathogenesis of neurodegenerative 
disorders. A major function of the neurovascular unit is to regulate the transport and 
diffusion properties of brain capillary endothelial cells that compose the brain-blood barrier. 
Astrocytes exhibit anatomic relationships with cerebral arterioles and neurons. In the brain 
parenchyma, the extensive ensheatment of cerebral arterioles by astrocytic end-feet far 
exceeds any direct neural contacts with those perfusion-regulating microvessels. That 
unique arrangement permits astrocytes to transduce signals arising from activated neurons 
and to transmit that information to the cerebral microcirculation. Alteration of these 
processes may play a particularly significant role in the pathogenesis of neurodegenerative 
diseases. The early and mid-term stages of neurodegenerative processes are associated with 
generalised atrophy of astroglia, whereas the later stages are characterized with an  
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astrogliosis and microglial activation linked to neuropathological lesions such as senile 
plaques (Rodriguez & Verkhratsky, 2010). 
Acute neurodegeneration is encountered during and following stroke, transient cardiac 
arrest, brain trauma, insulin-induced hypoglycemia and status epilepticus. All these severe 
clinical conditions are characterized by neuronal calcium overload, aberrant cell signaling, 
generation of free radicals and elevation of cellular free fatty acids, conditions that favor 
activation of the mitochondrial permeability transition pore (mtPTP) (Friberg & Wieloch, 
2002).  
Pathological cascade leading to clinical manifestations of chronic neurodegeneration (i.e. 
Parkinson’s disease, Alzheimer’s disease, Hungtington’s disease) includes progressive loss 
of functional synapses, irreversible damage and loss of neurons, neurotoxicity, and 
excessive activation of astroglial (reactive astrogliosis) and microglial (neuroinflammation) 
cells. Neurodegeneration is associated with axonal and synapse degeneration which is 
triggered by mechanical, metabolic, infectious, toxic, hereditary and inflammatory stimuli. 
Several signaling pathways are implicated in axonal and synapse degeneration, but 
identification of an integrative mechanism for these self-destructive processes has remained 
elusive. Also, neurodegenerative events are known to be associated with alterations in cell-
cell interactions, gene expression, dynamics of neuronal networks, development of oxidative 
stress, accumulation of lipid and protein oxidation products, production of fatty acids 
metabolites with biological activity, mitochondrial dysfunction, impairment of multiple 
signaling pathways, activation of programmed cell death (Salmina, 2009). 
In general, the link between the character of astroglial activation and neuronal damage or 
repair in neurodegeneration is well established (Theodosis et al., 2008). The current 
conception includes impairment of astroglia-assisted synapse formation and plasticity, 
synapse elimination, neurogenesis, function of neural circuits, and functioning of the blood-
brain barrier; dysregulation of gliovascular control and cerebral blood flow, alterations of 
neuronal metabolism, astrocyte-dependent augmentation of oxidative stress due to 
impaired antioxidant activity, stimulation of neuroinflammatory response, potentiation of 
excitotoxic insult, mitochondrial and glycolytic failure, impairment of glial calcium 
homeostasis, pathology of neurovascular unit, reactive astrogliosis accompanied by scar 
formation and initiation of brain repair (Bambrick et al., 2004; Barres, 2008; Buffo et al., 2008; 
L'Episcopo et al., 2010; Ricci, et al., 2009; Sofroniew, 2009; Stevens, 2008; Verkhratsky, et al., 
2010; Verkhratsky et al., 1998).   
Recent achievements in deciphering cell and molecular mechanisms of acute and chronic 
neurodegeneration suggest new prospective biomarkers and therapeutic targets for 
modulation of neuron-glia interactions. In this chapter, we will focus on several aspects of 
metabolism of nicotinamide adenine dinucleotide (NAD+) in neurons and astrocytes as a 
critical factor in neurodegeneration-associated cell damage. 
2. Neuronal and glial NAD
+
-generating and NAD
+
-converting enzymes in 
neurodegeneration 
Few decades ago, the actions of NAD+ have been extended from being an oxidoreductase 
cofactor for single enzymatic activities to acting as substrate for a wide range of proteins. 
These include NAD+-converting enzymes, and transcription factors that affect a large array 
of cellular functions. Through these effects, NAD+ provides a direct link between the cellular 
redox status and the control of signaling and transcriptional events (Houtkooper et al., 2010). 
Cellular bioenergetic homeostasis requires production and delivery of energy-rich  
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phosphoryls and NAD+. In cytosol, NAD+ and NADH mediate glycolysis acting as co-
factors for rate-limiting glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase, 
participate in lactate-pyruvate conversions, and affect mitochondrial oxidative 
phosphorylation. Also, NAD+ serves as a substrate for NAD+-converting enzymes (ADP-
ribosyltransferases, poly(ADP-ribosyl)polymerase and ADP-ribosyl cyclase). 
Synthesis of NAD+ in vivo and de novo is possible by means of 4 pathways: 1) from nicotinic 
acid (niacin); 2) from nicotinamide (vitamin PP); 3) from tryptophan; 4) from aspartate (in 
plants only). Recently, a biosynthesis pathway which uses nicotinamide riboside as a 
precursor has been described. For the synthesis of NAD+ from L-tryptophan, the indole ring 
should undergo transformation into the pyridine ring, and finally quinolinate is formed. 
Quinolinic acid undergoes further transformations resulting in NAD+ formation. 
Indoleamine 2,3-dioxygenase (expressed in various tissues) and tryptophan 2,3-dioxygenase 
(expressed in liver) catalyze the formation of N-formylkynurenine in the reaction 
representing the first rate-limiting step in this pathway. Indoleamine 2,3-dioxygenase is a 
unique enzyme in that it can utilize as the substrate, in place of oxygen, the superoxide 
anion radical, thus acting as a radical scavenger. The second rate-limiting step in this 
pathway is represented by the reaction catalyzing by quinolinate phosphoribosyltransferase 
responsible for the conversion of quinolinic acid and 5-phospho-ǂ-D-ribose 1-diphosphate 
to nicotinate mononucleotide, pyrophosphate and CO2 (Magni et al., 2004). 
Enzymes responsible for producing neuroactive compounds in the kynurenine pathway are 
preferentially localized in astrocytes and microglia. Astrocytes are well equipped with 
enzymes for kynurenine metabolism, i.e indoleamine 2,3-dioxygenase is highly expressed in 
these cells (Suh et al., 2007), thus raising the possibility that generation of the neuroactive 
compounds may play significant role in neuron-glial cell interactions (Ying, 2006). 
Interestingly, tryptophan and kynurenine stimulate expression of nerve growth factor in 
astrocytes (Dong-Ruyl et al., 1998), while interferon-gamma hyperactivates indoleamine 2,3-
dioxygenase resulting in elevated production of kynunerines (i.e. quinolinic and picolinic 
acids) and stimulation of iNOS in human aged brain and vascular cognitive impairment 
(Oxenkrug, 2007). In general, kynurenine pathway is up-regulated in Alzheimer’s disease 
brain, i.e. in hippocampus, where indoleamine 2,3-dioxygenase and quinolinic acid 
immunoreactivity was detected in astrocytes, microglia and neurons, with highest 
expression in glial cells in the perimeter of senile plaques. Quinolinic acid immunoreactivity 
was also present in granular deposits within the neuronal soma of cortex, and looks to label 
neurofibrillary tangles (Guillemin et al., 2005). Dysfunction of quinolinate metabolism in the 
human brain has been postulated to be involved in the pathogenesis of Alzheimer’s disease 
("quinolinate hypothesis") (Fukuoka et al., 2002). At the same time, it was suggested that 
astrocytes alone are neuroprotective by minimizing quinolinic acid production and 
maximizing synthesis of kynurenic acid (due to absence of kynurenine hydroxylase), but in 
the presence of macrophages and/or microglia, astrocytes become indirectly neurotoxic by 
the production of high concentrations of kynurenine that can be secondary metabolized by 
neighboring cells to quinolinic acid (Guillemin et al., 2001).  
Mononucleotide adenylyltransferase (NMNAT) is a central enzyme in NAD+ biosynthesis, 
catalyzing the condensation of nicotinamide mononucleotide or nicotinic acid 
mononucleotide with the AMP moiety of ATP to form NAD+. NMNAT-1 has nuclear 
localization, and was proposed to have functional relations with poly (ADP-ribosyl) 
polymerase (PARP) in prevention of NAD+ depletion during PARP over-activation. 
NMNAT-2 isoform has cytoplasmic localization, and is very prone to oxidation due to 
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presence of nine cysteines versus four cysteines present in NMNAT-1. NMNAT-3 presents 
in cytoplasm and mitochondria, has much lower enzymatic activity comparing with 
NMNAT-1 and NMNAT-2 (Raffaelli et al., 2002). Extracelullar nucleotides (e.g. NAD+ and 
NMN) undergo extracellular degradation resulting in the formation of permeable 
precursors which are further converted to NAD+ in mitochondria due to activity of 
NMNAT3 localized to the mitochondrial matrix (Nikiforov et al., 2011). Interestingly 
enough, in genomewide screen for late-onset Alzheimer’s disease, SNP of the NMNAT-3 
gene was found, thus suggesting involvement of NAD+ synthesizing pathways in 
pathogenesis of this neurodegenerative disorder (Liu et al., 2007)].  
Recently, a role for mitochondrial permeability transition, and mitochondrial dysfunction, in 
development of axonal degeneration has been proposed. Axonal degeneration has been 
shown to be regulated by proapoptotic proteins (i.e. caspases 3 and 6) and/or NAD+-
sensitive pathways (Schoenmann et al., 2010). Since these degenerative processes can cause 
permanent loss of function, they represent a focus for neuroprotective strategies (Barrientos 
et al., 2011). Functioning of NMNAT as a chaperone acting through a proteasome-mediated 
pathway was found (Zhai et al., 2008), thus suggesting novel aspects in regulation of NAD+ 
homeostasis under the conditions of cellular stress. Overexpression of NMNAT in the 
mitochondrial matrix resulted in suppression of axonal degeneration seen in 
neurodenegeration (Sasaki & Milbrandt, 2010; Sasaki et al., 2009; Yahata et al., 2009). In 
amyloid-treated cells, NMNAT-sensitive program is uniquely involved in axonal, but not 
cell body, degeneration (Vohra et al., 2010). Axonal degeneration can be slowed by the 
addition of extracellular NAD+ (Billington et al., 2008). 
Nicotinamide N-methyltransferase (NNMT) methylates pyridines, in particular nicotinamide, 
to N-methyl nicotinamide which is further used for synthesis of NAD(P) and NAD(P)H. 
Increased activity of NNMT leads to cellular nicotinamide deficiency. It was demonstrated 
that elevated levels of NNMT result in reduced Complex I activity in idiopathic Parkinson's 
disease (IPD) in two ways: (1) reduction in the levels of nicotinamide available for 
nicotinamide adenine dinucleotide synthesis; and (2) increased methylation of compounds 
such as tetrahydroisoquinolines and ǃ-carbolines, which are potent Complex I inhibitors. 
Expression of NNMT is increased in Parkinson’s disease which may ultimately lead to 
neurodegeneration via a reduction in Complex I activity (Parsons et al., 2003). A.C.Williams 
has proposed that elevated activity of NNMT may be responsible for dopaminergic toxicity 
of N-methylated pyridines (i.e. MPP+) and for depletion of NAD+ in the cells (Williams et 
al., 2005). 
Apart from the pathways of NAD+ synthesis de novo, there are some reactions for the 
regeneration of NAD+ from molecules formed during its functioning and catabolism 
(reduced pyridine nucleotides (NADH, ADP-ribose, nicotinamide, NAAD+). It should be 
noted that re-synthesis of NAD+ from ADP-ribose and nicotinamide requires as many as 
four molecules of ATP, therefore being energetically unfavorable (Di Lisa & Ziegler, 2001). 
Regeneration of NAD+ from NADH may be achieved through the activity of following 
enzymes and processes: 1) specific NADH flavin dehydrogenase acting in the respiratory 
chain; 2) transhydrogenase of the outer mitochondrial membrane; 3) specific NADH 
oxidases; 4) malate-aspartate shuttle. Regeneration of NAD+ is very important not only for 
the economic using of cellular pool of pyridine nucleotides, but also for their effective 
intracellular redistribution at the appropriate moment under physiological and pathological 
conditions. Murine glial cells have been shown to synthesize NAD+ from quinolinic acid, 
www.intechopen.com
Alteration of Neuron-Glia Interactions in Neurodegeneration:  
Molecular Biomarkers and Therapeutic Strategy 
 
277 
however, the pathway for NAD+ regeneration from nicotinic acid is a preferred route for 
NAD+ biosynthesis (Grant & Kapoor, 1998).  
Among all the NAD+-converting enzymes, poly(ADP-ribosyl) polymerase (PARP) and 
ADP-ribosyl cyclase attract the main attention in terms of neurodegenerative disorders 
(Kauppinen & Swanson, 2007). Poly(ADP-ribosyl) polymerase functions as DNA damage 
sensor and signaling molecule binding to single- and double-stranded DNA breaks. Upon 
binding to damaged DNA PARP forms homodimers and catalyzes the cleavage of NAD+ 
into ADP-ribose and nicotinamide. ADP-ribose is then used to synthesize the branched 
polymer attached to nuclear (or mitochondrial) acceptor proteins. Variety of acceptor 
proteins has been described (histones, DNA repair enzymes, topoisomerases, transcription 
factors, DNA-dependent protein kinase, lamin B, p53), but the most efficient acceptor 
appears to be the enzyme itself (Ziegler, 2000). 
There is a growing number of evidences on involvement of PARP and PARP-mediated 
depletion of intracellular NAD+ in the acute and chronic injury of cells 
(ischemia/reperfusion, endothelial dysfunction, genotoxicity, inflammation, traumatic 
injury) (Oliver et al., 1999). In respect to the CNS, NAD+ depletion and mitochondrial 
permeability transition were shown to be sequential and necessary steps in PARP-1 
overactivation-dependent cell death in astrocytes (Alano et al., 2004). Increased poly(ADP-
ribosylation) of nuclear proteins was demonstrated in neurons in Alzheimer’s disease (Love 
et al., 1999). Intra-mitochondrial PARP contributes to NAD+ depletion and cell death 
induced by oxidative stress in neurons (Du et al., 2003). Increased poly ADP-ribosylation of 
nuclear proteins in Alzheimer’s disease has been detected, and double immunolabelling for 
poly(ADP-ribose) and markers of neuronal, astrocytic and microglial differentiation showed 
many of the cells containing poly(ADP-ribose) to be neurons, while few of the cells were 
astrocytes, and no poly(ADP-ribose) accumulation was found in microglia (Kauppinen & 
Swanson, 2007; Love, et al., 1999). Moreover, it was shown that ǃ-amyloid affected 
cholinergic receptor-mediated signal transduction to PARP, probably, through free radical 
evoked inhibition of inositol-3-phosphate formation in the hippocampal cells (Adamczyk et 
al., 2005). Glutamate neurotransmission involving NMDA receptors and neuronal nitric 
oxide synthase activity in part mediates neuronal DNA strand breaks and PARP activation. 
These events are especially important for neurons since astrocytes able to maintain higher 
levels of NAD+ comparing with neurons (Pieper et al., 2000), and much higher 
concentrations of oxidants are required for killing astrocytes (Ying et al., 2002). It should be 
taken into the consideration that excessive PARP activation leads to impairment of 
glycolysis in affected cells, thereby impaired glycolytic flux is involved into PARP-mediated 
neuronal and astroglial cell death. Since astrocyte-produced lactate is a major endogenous 
energy substrate used by neurons in brain, NAD+ depletion caused by excessive PARP 
activation in neurons would result in alteration of lactate-pyruvate conversion thus  
affecting the efficacy of oxidative metabolism in neurons and astrocyte-neuronal lactate 
shuttle mechanism. In addition, neurological metabolic coupling implies subcellular 
compartmentation of pyruvate and monocarboxylate recycling through the plasma 
membrane of both neurons and glial cells, subcellular compartmentation of pyruvate allows 
neurons and astrocytes to select between glucose and lactate as alternative substrates 
depending of the concentrations and the operation of a redox switch (Cerdan et al., 2006). 
Pyruvate compartmentation results in effective transcellular coupling between the cytosolic 
NAD+/NADH redox states of neuronal and glial cells, therefore, impairment of this 
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mechanism due to PARP hyperactivation in neurons could directly affect restoring the basal 
redox state in astrocytes.  
Another class of enzymes utilizing NAD+ is represented by the CD38 family (EC 3.2.2.5, EC 
3.2.2.6). Two ligands of CD38 – the substrate ligand NAD+ acting either extracellularly or 
intracellularly, and the non-substrate ligand CD31 expressed in endothelial cells – have 
important functions in brain cells under (patho)physiological conditions (Higashida et al., 
2001a; Higashida et al., 2007; Salmina et al., 2010a; Salmina et al., 2006b). CD38 possesses the 
capability to catalyze different reactions, such as the hydrolysis of NAD+ and cADPR to 
ADP-ribose, and the cyclization of NAD+ and nicotinamine guanine dinucleotide (NGD+) to 
cADPR and cGDPR, respectively. The physiological meaning of the latter reaction is still 
unclear, but biological activity of cADPR is well defined in many cell types (Deaglio et al., 
2008; Malavasi et al., 2008a). ADP-ribosyl cyclase attributable to CD38 was detected in the 
central nervous system where its activity and expression showed developmental changes. 
ADP-ribosyl cyclase synthesizes Ca2+ mobilizing messengers by cyclizing NAD+ to produce 
cyclic ADP-ribose (cADPR) acting through activation/modulation of ryanodine receptor 
channels involving FKBP12.6. In addition, cADPR was also shown to affect some potassium 
currents and thereby could be involved in synaptic activity. In murine brain, CD38 was 
found in both neurons and glial cells, showed predominant intracellular location, and was 
enriched in neuronal perikarya. In human brain, CD38 immunoreactivity was demonstrated 
in neurons, astrocytes, and microglial cells. In rat astrocytes, ADP-ribosyl cyclase has been 
reported to have both intracellular and extracellular actions. Co-culture of astrocytes with 
neurons resulted in significantly increased expression of astrocytic CD38 both on the plasma 
membrane and cytosol, and this effect was attributed to neuron-released glutamate action 
on astrocytes (Bruzzone et al., 2004). It is known that astrocytic response to neuronal activity 
can be most readily detected by observing changes in the intracellular Ca2+ concentrations 
mediated via calcium flux trough the plasma membrane calcium channels or calcium release 
from intracellular stores. Subtype-specific coupling with ADP-ribosyl cyclase of various 
neurotransmitter receptors confirms the involvement of this enzyme in signal transduction 
in neuronal and glial cells. The expression of CD38 is regulated by various substances 
(cytokines, retinoic acid), while  enzymatic activity of ADP-ribosyl cyclase/CD38 is 
controlled by the structure of the catalytic center, the integrity of the sulfhydryl cysteine 
residues in this center, the intracellular levels of ATP and NADH, intracellular localization 
of the enzyme (plasma membrane, mitochondrial membrane, nuclear membrane, and 
cytosol), conformational plasticity, ligands (NAD+, CD31), and capacity to form dimers in a 
membrane for effective transport of reaction product.  
In the cells of the CNS, ADP-ribosyl cyclase is expressed in different cell compartments (the 
nucleus, cytosol, and mitochondria), including the plasma membrane; however, the 
mechanisms that control translocation of the enzyme molecules, role of intracellular 
localization in the realization of enzymatic activity, and the mechanisms of directed 
transport of the enzyme to different cell compartments are unclear (Higashida et al., 2001; 
Salmina et al., 2008). Proposal exists that CD38 is a regulator of cellular NAD+ levels under 
physiological conditions, while PARP is the key factor determining intracellular NAD+ 
levels when significant DNA damage occurs (Ying et al., 2005). 
A key role of CD38 in regulation of NAD+ homeostasis in cells has been suggested (Aksoy et 
al., 2006). Thereby, CD38 may contribute to regulation of activity of SIRT proteins or TRPM 
(transient receptor potential) channels. SIRT1 promotes survival and stress tolerance in brain  
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cells. SIRT expressed in neuronal and astroglial cells requires NAD+ as an essential cofactor 
for their deacetylase activity, thus providing direct link between the metabolic and 
transcriptional response (Cohen et al., 2009; Kwon & Ott, 2008), while TRPM2 channels are 
expressed predominantly in neurons and microglia and are activated by cyclic ADP-ribose 
or by NAD+ (Togashi et al., 2006). 
It is known that astrocytic response to neuronal activity can be most readily detected by 
observing changes in the intracellular Ca2+ concentrations mediated via calcium flux 
through the plasma membrane calcium channels or calcium release from intracellular stores. 
Products of enzymatic activity of CD38 – cyclic ADP-ribose (cADPR) and nicotinic acid 
adenine dinucleotide phosphate (NAADP+) – work as potent Ca2+ mobilizing second 
messengers acting at ryanodine receptors (Higashida, et al., 2001a). Immunocytochemical 
studies revealed association of altered Ca2+ regulation in astrocytes (i.e. calcineurin up-
regulation) with their activation in aging or Alzheimer’s disease models (Norris et al., 2005). 
Functional ryanodine receptors are required for astrocyte migration that is important 
component of regenerative process in the brain (Matyash et al., 2002). Therefore, expression 
and functional activity of CD38 in astrocytes and/or neurons, and ectocellular action of 
cADPR and NAADP+ on astrocytes resulting in Ca2+ signaling (Heidemann et al., 2005; 
Pawlikowska et al., 1996) would have physiological and pathophysiological meaning as a 
mechanism of Ca2+ signaling involved in neuron-astroglia cell interactions. Alterations in 
ryanodine receptor binding and function are very early events in the pathogenesis of 
Alzheimer’s disease (Kelliher et al., 1999) while Aǃ increases ryanodine receptors expression 
and function in cortical neurons (Supnet et al., 2006). Taking into account importance of 
neuronal calcium mishandling in the development of Alzheimer’s disease (Verkhratsky, et 
al., 1998), one can suggest involvement of cADPR-associated signaling pathways in 
observed ryanodine receptor dysfunction.  
Figure 1 summarizes data on NAD+-generating and NAD+-converting pathways in 
mammalian cells. 
3. Astroglial CD38 and Cx43 in neuron-glia metabolic coupling  
Glial cells can communicate with each other by means of Ca2+ waves, and any perturbation 
of astrocytic intracellular concentration can propagate to other adjacent astrocytes through 
gap junction formed by connexins (Cx). Astroglial calcium signaling can be linked to 
synaptic transduction between neurons and neuronal-astroglial metabolic coupling 
(Allegrini et al., 2009). Cx43-formed gap junctions extensively couple neurons with glia 
(Nagy et al., 2004), and astrocytes represent the largest gap junction-coupled cellular 
network within the brain (Nakase & Naus, 2004).  In the adult brain, Cx43 levels vary 
according to the developmental stage and brain region: Cx43 is expressed from early in 
development and further its expression increases.Cx43 is believed to be mediator of 
intercellular communication and operator between processes originating from a single 
astrocyte. In astrocytes, connexons are activated at metabolic inhibition, pro-inflammatory 
microenvironment, brain injury. Cx43 contributes to paracrine pathways in astroglial cells 
by regulating Ca2+ waves and uptake and release of glutamate, ATP, glucose, and 
glutathione (Giaume et al., 2010).  
Astroglial cells express connexin-based gap junction channels and hemichannels that allow 
passage of molecules between the cytoplasm and extracellular cells or between the cells  
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Fig. 1. Metabolism of NAD+ in mammalian cells. Abbreviations used: NAPRT – nicotinic 
acid phosphoribosyltransferase, NAMPT – nicotinamide phosphoribosyltransferase,  
NRK – nicotinamide riboside kinase, NaMN – nicotinic acid mononucleotide,  
NMN – nicotinamide mononucleotide, QPRT – quinolinate phosphoribosyltransferase, 
NMNAT – nicotinamide mononucleotide adenylyltransferase, NAAD – nicotinic acid 
adenine dinucleotide, NAD+ - nicotinamide dinucleotide 
(Contreras et al., 2004). Synapse-glial interactions in the developing, adult and injured brain 
are very important for brain plasticity. Distinct phases of synapse development depend on 
assistance from glial cells (Pfrieger, 2010). Astrocytic hemichannels consisted of connexin 43 
mediate release of glutamate and other amino acids (Ye et al., 2003). Gap junction channels 
allow the coordination of intrinsic or elicited metabolic and/or electrical responses of cells in 
a heterogenous population, and regulate poroliferative activity of astroglial cells. Astrocytes 
with a radial glia–like morphology in the subgranular zone of the dentate gyrus are 
considered as stem cells which give rise to neurons within different regions of the adult 
brain. Radial glia-like cells express GFAP, nestin, and Cx43. The latter contribute to  
controlling proliferation and differentiation of these cells since no other mechanisms (i.e. 
glutamatergic) have been detected in radial glia-like cells (Kunze, 2009). 
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Two primary hypotheses of gap junction coupling in the CNS are the following: (1) 
generalized coupling occurs between neurons and glia, with some connexins expressed in 
both neurons and glia, and (2) intercellular junctional coupling is restricted to specific 
coupling partners, with different connexins expressed in each cell type. The most important 
question is a role of connexon in mediating communication between different cell types in 
the brain (Rash et al., 2001). It is well-known that intercellular calcium signaling between 
different types of glial cells (astrocytes and oligodendocytes) is mediated by Cx43 (Parys et 
al., 2010). Several connexin proteins have been identified at gap junctions between neuronal 
and astroglial cells. Moreover, expression of Cx43 but at much lower levels comparing to 
astrocytes has been detected in oligodendrocytes, Schwann cells and neurons (Nagy, et al., 
2004). However, astrocytes are still considered as connexin-dependent signaling cells (Saez, 
2008). Expression of Cx43 is closely related to the role of astrocytes in coordinating the 
neuronal signals and local blood flow (neurovascular coupling). 
In the CNS, expression and activity of Cx43 are modulated by cytokines, NO. Recently, 
novel protein interacting with Cx43 in astrocytes has been identified – brain-derived 
integrating factor-1 (BDIF-1) which is probably involved in regulating of astroglial activity 
(Ito et al., 2011). Pharmacological modulation of Cx43 can be achieved by various 
compounds (Dhein et al., 2002). T. Nakase et al. (Nakase & Naus, 2004) reported that the 
activation of astrocytes associated with an increase in the expression and activity of 
connexin 43 protects neurons from ischemia-induced damage. It should be noted that Cx43 
can provide NAD+ to the ectodomain of CD38. In fibroblasts, Cx43 hemichannels mediate 
release of NAD+ to the extracellular medium, presumably allowing cytoplasmic NAD+ to 
reach the active site of ADP-ribosyl cyclase/CD38 located at the extracellular part of plasma 
membrane (Franco et al., 2001). The same mechanism could work in astrocytes (Verderio et 
al., 2001) since glutamate-induced CD38 overexpression in astrocytes was observed in the 
model of neuronal-astroglial cell coupling. Functional cross-talk between Cx43 
hemichannels and CD38 may be triggered by elevation of intracellular Ca2+ concentrations 
or by binding of a ligand to Cx43 or CD38. De Flora et al. (De Flora et al., 2004) suggested 
that extra phosphorylation of Cx43 induced by Ca2+ rise decreases the open-state probability 
of connexons, thereby downregulating NAD+ transport across them and resulting in lower 
access of NAD+ to the active site of CD38 and decreasing cADPR generation and limiting of 
Ca2+ levels inside the cell. Thus, autocrine and paracrine Ca2+ signaling is mediated by Cx43-
CD38 system. Whether or not such system is operating in astrocytes in the context of 
neuronal-astroglial coupling remains to be elucidated. This mechanism is very important, 
because it helps to prevent NAD+ loss from cells, depletion of intracellular NAD+ due to 
elevated CD38 activity, and cADPR overproduction leading to calcium accumulation to 
toxic levels (Salmina et al., 2009a). 
CD38 and Cx43 also may serve as transporters of nucleotides (NAD(H), cADPR, and 
NAADP+) into the cell from the extracellular space (Billington, et al., 2008), thus 
contributing to maintaining NAD+ homeostasis within the cell. NAD+ itself can enter 
astrocytes via gap junction-mediated pathway (Ying, et al., 2005). 
What are the possible roles for Cx43 hemichannes in neurodegenerative processes? Elevated 
expression of Cx43 in reactive astrocytes may reflect: 1) extensive buffering of neurotoxic 
substances by activated astroglial cells required for protecting the neurons from cell death 
(i.e. inhibition of gap junctions with octanol abolishes the ability of Aǃ to enhance the 
velocity and extent of propagation of astroglial calcium waves (Orellana et al., 2009));  
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2) propagating Ca2+ waves between communicating astrocytes and/or individual processes 
of a single cell; 3) active proliferation and migration of Cx43-immunopositive progenitor 
cells to the site of neurodegeneration; 4) activation of autocrine and paracrine signaling in 
astrocytes and adjacent neurons; 5) action of stimuli (prooxidant and proinflammatory) able 
to increase Cx43 expression.  In neurodegenerative diseases and ischemia, reactive 
astrocytes have increased levels of Cx43, and changes in Cx43 expression are dependent on 
the proximity of the reactive astrocytes to the focus of neurodegeneration. In the site of 
injury, reactive astrocytes can lose their non-overlapping domains (Giaume, et al., 2010). 
Functional hemichannels that have a role in glutamate homeostasis may significantly 
contribute to astrocyte-mediated regulation of neuronal activity. It is interesting that in the 
Alzheimer’s type of neurodegeneration, elevated expression of Cx43 has been detected at  
ǃ-amyloid plaques due to reactive astrogliosis (Mei et al., 2010). It was suggested that in 
Alzheimer’s disease, increased Cx43 expression might represent an attempt to maintain 
tissue homeostasis by augmented intercellular communication via gap junction formation 
between astrocytic processes that invest senile plaques. In addition, one can propose that 
elevated expression of Cx43 hemichannels could result in massive release of glutamate 
from astrocytes into the extracellular space resulting in excitotoxic injury of neurons. 
Connexin 43 regulates astrocytic migration and proliferation in response to injury. Reactive 
astrocytes display up-regulation of the gap junction protein Cx43, and astroglial cells with 
depleted expression of Cx43 show diminished ability to migrate and to proliferate in the 
wound area of the brain (Homkajorn et al., 2010). Drebrin as an actin binding protein 
whose level is greatly decreased in brains of Alzheimer’s patients was found to be a 
binding partner of the Cx43 COOH-terminal domain in astrocytes. In experimental model, 
depletion of drebrin in cells results in impaired cell-cell coupling, internalization of gap 
junctions, and targeting of Cx43 to a degradative pathway (Butkevich et al., 2004)]. It was 
suggested that increased Cx43 expression in a close vicinity to amyloid plaques might 
represent aberrant induction of Cx43 expression stimulated by excessive degradative 
pathway. In support of this hypothesis, increased expression of Cx43 was found to be 
induced by ǃ-amyloid precursor protein (Hallaq & Killick, 2006)], thus suggesting direct 
effect of amyloid deposites on the mechanism of glutamate release from astroglial cells and 
neuron-astrocyte communication. 
Recently, changes in expression and activity of Cx43 have been registered in rotenone-
induced model of Parkinson’s disease: enhancement of Cx43 protein levels in cells treated 
with rotenone (mitochondrial complex I inhibitor) resulted in increased efficacy of gap 
junctional intercellular communication (Kawasaki et al., 2009). However, some authors 
registered inhibited expression of astrocytic Cx43 and gap junction permeability in 
astrocytes in rotenone models of Parkinson’s disease. Moreover, rotenone-induced 
dysfunction of astrocytic Cx43 can be reversed by opening mitochondrial ATP-sensitive 
potassium channels (iptakalim and diazoxide) resulting in prevention of astrocyte apoptosis 
(Zhang et al., 2010). Thus, we believe that Cx43-CD38 functional coupling in astrocytes 
significantly contribute to controlling energy homeostasis in astroglial and neuronal cells.  
Opening of the mitochondrial permeability transition pore is known to play a role in cell 
death. Its opening has been shown to cause activation of NAD+ glycohydrolase located in 
the outer mitochondrial membrane following by NAD+ hydrolysis in cardiomyocytes at 
postischemic reperfusion (Di Lisa et al., 2001). Since mitochondrial NAD+ glycohydrolase 
has been identified as ADP-ribosyl cyclase (Ziegler et al., 1997), NAD+ released from 
mitochondrial matrix could be transformed into cADPR which promoting Ca2+ release from 
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intracellular stores. Thereby, amplification of initial rise in intracellular Ca2+ levels might be 
important in cell damage. It was reported that mitochondrial dysfucntion leads to 
postponed changes in CD38 expression (Mills et al., 1999). Thus, accumulating data suggest 
that ADP-ribosyl cyclase may affect mitochondrial functioning through various 
mechanisms. 
Mitochondrial localization of Cx43 has been shown in cardiomyocytes, and the role for Cx43 
as regulator of mitochondrial potassium uptake (Miro-Casas et al., 2009) or mitochondrial 
respiration (Boengler et al., 2008a) has been suggested. Stimulatory effect of Cx43 on 
mitochondrial KATP channels resulting in cytoprotectiion has been shown in 
cardiomyocytes (Rottlaender et al., 2010). It is intriguing to speculate that mitochondrial 
Cx43 contributes to regulation of respiration and potassium uptake in astroglial cells, thus 
providing adaptation of mitochondrial activity to altered microenvironment in activated 
astrocytes in the site of brain injury. It was proposed that Cx43 may directly regulate 
respiratory chain complex I activity and mitochondrial oxygen consumption: decrease in 
mitochondrial Cx43 levels reduced complex I activity (Boengler et al., 2008b). 
Mitochondrial localization of CD38 is well documented. I. Balan et al. (Balan et al., 2010) 
detected NAD+- glycohydrolase activity in isolated synaptosomes and also in intact brain 
mitochondria, confirming localization of CD38 also in outer mitochondrial membranes. 
Interestingly, the NAD+- glycohydrolase activity appeared to be much higher in 
nonsynaptic mitochondria compared with mitochondria isolated from synaptosomes. Taken 
together, these data suggest that NAD+ depletion can occur more rapidly in astrocytes 
following ischemic insult, compromising the ability of astrocytes to support neuronal 
functions. Interestingly, the NAD+  catabolic activity is higher in brain regions that are 
vulnerable to ischemic insult, furthermore, the CD38 NAD+ glycohydrolase activity is 
significantly increased in postischemic tissue, and the immunohistochemistry shows 
overexpression of this enzyme preferentially in neuroglial cells (Kristian et al., 2011; 
Salmina, et al., 2008; Salmina, et al., 2009a). Activation of CD38 can lead to rapid and almost 
complete tissue NAD+ depletion (Balan, et al., 2010). A prolonged MPT results not only in 
dissipation of the mitochondrial electrochemical hydrogen ion gradient and swelling of 
mitochondria but also depletion of pyridine nucleotides from the matrix (Di Lisa & Ziegler, 
2001), however, significant loss of matrix pyridine nucleotides can lead to inhibition of 
mitochondrial respiration but without irreversible damage to the respiratory complexes or 
mitochondrial membranes (Kristian, et al., 2011). It was proposed, that once the cellular 
CD38 enzymatic pool is saturated, cytosolic NAD+ concentrations rise to a level that permits 
efflux into extracellular space where NAD+ becomes to be the substrate for surface-
expressed CD38 acting as autocrine or paracrine regulator of Ca2+ signaling.  
Neurodegeneration is associated with altered energy metabolism in the brain;  accumulation 
of glycolytic enzymes, such as enolase and glyceraldehyde 3-phosphate dehydrogenase, 
decrease in expression of voltage-dependent anion-selective channel protein-1 (VDAC-1), 
and decrease in expression of subunits of multiprotein enzyme complex NADH:ubiquinone 
oxidoreductase (complex I of the mitochondrial electron transport chain) have been 
registered in Alzheimer’s disease (Butterfield et al., 2003)]. It is well known that astrocytes 
play important roles in supporting energy production in neurons. According to astrocyte-
neuron lactate shuttle hypothesis, lactate is produced in an activity-dependent and 
glutamate-mediated manner by astrocytes and is then transferred to and used by active 
neurons (Pellerin et al., 1998). Neuronal activation results in uptake of glutamate by 
astrocytes leading to activation of glutamine synthetase and Na+-K+-ATPase, followed by 
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activation of anaerobic glycolysis in astrocytes, and release of lactate supporting the activity-
related energy required for neurons (Magistretti, 2000)]. In general, astrocytes metabolize 
glucose mainly to lactate and release it into the extracellular medium, while neurons appear 
to have a kinetic preference for oxidizing lactate imported from the external medium over 
pyruvate/lactate produced in neurons by glycolysis (Itoh et al., 2003). However, neurons die 
more intensively than astrocytes even though the apparent dysfunction takes place in 
astrocytes. Glycolysis is high in astrocytes, so they need a way to maintain the adequate 
levels of NAD+. Probably, astrocytes can sustain themselves adequately with glycolytic 
metabolism, not significantly affected by mitochondrial dysfunction, thereby being more 
resistant to oxidative stress and NAD+ depletion.  
4. CD38 expression in acute and chronic neurodegeneration 
Very few data are available on CD38 expression in neurodegeneration. In different 
experimental models of acute and chronic neurodegeneration in rats (focal brain ischemia, 
rotenone model of Parkinson’s disease, and perinatal hypoxic-ischemic brain injury), we 
found elevated expression of CD38 in neurons and astroglial cells in the acute period of 
brain injury (Salmina, et al., 2008; Salmina, et al., 2009a; Salmina et al., 2006a).  
In the model of perinatal hypoxic-ischemic brain damage, we found that changes in CD38 
expression and ADP-ribosyl cyclase activity in neuronal and glial cells attribute to 
alterations in intracellular NAD+ level as well as to  susceptibility of the cells to the action 
of apoptogenic stimuli; acute period of perinatal hypoxic/ischemic brain injury is 
characterized by reactive astrogliosis and elevation of CD38 expression, changes in CD38 
and Cx43 expression in astrocytes serving as markers of neuron-glial interactions in 
perinatal CNS injury; ADP-ribosyl cyclase activity in neurons in response to stimulation 
of NMDA is changed after perinatal hypoxic-ischemic brain injury. It has been 
demonstrated that, in the immature brain, the impairment of intracellular calcium 
homeostasis is the leading mechanism of perinatal damage to both neuronal and glial cells 
(Vannucci et al., 2001). Based on our data, we can conclude that the mechanisms of 
maintenance of intracellular calcium homeostasis, which are under the control of ADP-
ribosyl cyclase and Cx43, play a special role in responses of neurons and glia to hypoxic–
ischemic damage.  
We demonstrated that most of the cells that expressed Cx43 were CD38-immunopositive in 
acute neurodegeneration. Interestingly, in the 10-day-old rats subjected to cerebral damage, 
the number of Cx43 and CD38 coexpressing cells was several times higher as compared to 
GFAP and CD38 coexpressing cells, whereas the fractions of cells that expressed both GFAP 
and CD38 were similar in the control and experimental groups. These data suggest that 
other types of Cx43-containing cells, such as microglia, substantially contributed to the total 
elevation in CD38 expression after perinatal brain damage. Taking into account the data on 
the functional coupling of CD38 ADP-ribosyl cyclase activity and connexin 43, we studied 
the effects of a connexin blocker, glycyrrhetinic acid (GRA), on ADP-ribosyl cyclase activity 
in astrocytes isolated from brain tissue of control and experimental animals. We found that a 
30-minute incubation of astrocytes with 5μM GRA resulted in decrease in ADP-rybosyl 
cyclase activity in these cells (Salmina, et al., 2009a). 
In the model of focal brain ischemia in adult animals, we confirmed that CD38 could be 
considered as a marker of neuron-glia interactions disturbances caused by acute ischemic 
injury, and that modulation of ADP-ribosyl cyclase/CD38 expression and activity in the 
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brain significantly improved clinical manifestations of neurological dysfunction associated 
with ischemia-induced neurodegeneration (Salmina, et al., 2006a).  
In patients with ischemic stroke, elevated expression of CD38 in peripheral blood leukocytes 
corresponds to formation of membrane-derived microparticles and progression of 
endothelial dysfunction due to CD38-CD31 interactions (Inzhutova et al., 2008; Salmina et 
al., 2010b). It is well known that astrocytes play important role in the formation, extent and 
configuration of the junctional complexes in the brain endothelium in a manner that 
astrocyte-induced enhanced tight junction communication is associated with the reduction 
of gap junctions. A major function of the neurovascular unit is to regulate the transport and 
diffusion properties of brain capillary endothelial cells that compose the brain-blood barrier 
(Banerjee & Bhat, 2007). Astrocytes exhibit anatomic relationships with cerebral arterioles 
and neurons. In the brain parenchyma, the extensive ensheatment of cerebral arterioles by 
astrocytic end-feet far exceeds any direct neural contacts with those perfusion-regulating 
microvessels. That unique arrangement permits astrocytes to transduce signals arising from 
activated neurons and to transmit that information to the cerebral microcirculation (Xu et al., 
2008). 
Coupling of NMDA receptors to ADP-ribosyl cyclase/CD38 in neuronal and glial cells, 
involvement of CD38 in neuronal-glial (Higashida et al., 2007a; Salmina, et al., 2009a) and 
leukocyte-endothelial interactions (Deaglio, et al., 2008; Inzhutova, et al., 2008; Malavasi et 
al., 2008) suggest new approach to treat endothelial dysfunction caused by various stimuli, 
i.e. by homocysteine (Boldyrev, 2010) in neurodegenerative processes. 
As we mentioned above, in acute neurodegeneration, CD38+-expressing cells were 
predominantly represented by GFAP+/Cx43+ cells of astroglial origin. We found that in 
neurons, elevated CD38 expression resulted in intracellular NAD+ depletion and cell death, 
while in astrocytes high levels of CD38 expression relate to increased resistance to the action 
of apoptogenic stimuli, development of reactive gliosis, and changes in their glycolytic 
activity. Mitochondrial ADP-ribosyl cyclase activity was mainly induced by ischemic 
stimuli. Our data well fit the previous observations that intracellular NAD+ levels regulate 
astroglial response to neuronal activation, NAD+ released from astrocytes regulate apoptosis 
of neurons in postischemic period, and astrocytes are more resistant to hypoxia than 
neurons. 
In the developing brain, direct correlation between the CD38 expression and apoptosis 
development in the given cell populations has been registered. We found stimulating effects 
of agonists of mGluRI, mGluRIII, suppressive effects of agonists of NMDAR on CD38 
activity in premature injured brain cells. However, in the adult brain, reverse correlation 
between CD38 expression and apoptosis progression was observed. Under the 
pathophysiological conditions, development of cell death and ability of brain cells to 
maintain the levels of intracellular NAD+ are determined by hypoxia/ischemia-induced 
disturbance in the dynamics of ADP-ribosyl cyclase activity in the brain cells. These data are 
in agreement with our report on the contribution of CD38 overexpression to development of 
plasma membrane blebbing in neuroblastoma x glioma NG108-15 hybrid cells (Egorova et 
al., 2000).  
In the experimental model of Parkinson’s disease, we found that loss of dopaminergic 
neurons via apoptosis was associated with elevation of expression and activity of  
ADP-ribosyl cyclase/CD38 in remaining tyrosine hydroxylase-immunopositive cells. 
Immunochemical studies with anti-CD38 antibodies indicated accumulation of CD38 
antigen in the neurofibrillary tangles that occur in neuronal perikarya and proximal 
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dendrites in Alzheimer’s disease (Otsuka et al., 1994). Literature data suggest that in 
Alzheimer’s disease, accumulation of CD38 antigen in the neurofibrillary tangles, an 
association of altered Ca2+ regulation in astrocytes, alterations in ryanodine receptors 
binding and functions are detectable.  
Dramatic rise in CD38 messenger RNA levels in IL-1ǃ-activated astrocytes was reported in 
HIV-associated neurodegeneration and dementia: in astrocytes, pre-treatment with the 
cADPR-specific antagonist 8-Br-cADPR and CD38 siRNA transfection returned elevated 
[Ca2+]i to baseline, thus confirming a CD38-cADPR specific response. These data have 
broader implications in other inflammatory diseases involving astrocyte activation and 
CD38 dysregulation (Banerjee et al., 2008). 
We suggest that possible causes of elevation of CD38 expression in brain cells are the 
following: 1) changes in NAD+ bioavailability (release from mitochondria into cytosol, cell 
death, connexin Cx43 activation); 2) redistribution of the enzyme in the cells; 3) cytokine-
dependent (IL, TNF) changes in expression of gene encoding for CD38 in the sites of brain 
injury of neurodegeneration; 4) action of neuro- and gliotransmitters. Since CD38 expression 
in astrocytes is stimulated by glutamate release from neurons, we can suggest that CD38 is a 
marker of altered neuron-astrocyte interactions under the conditions of excitotoxic insult. 
Also, since mitochondrial complex I dysfunction causes elevation of CD38 expression, we 
suggest that CD38 is a marker of mitochondrial dysfunction in the context of neuron-glia 
metabolic coupling. Activity of Cx43 prevents NAD+ depletion in CD38-overexpressing 
astrocytes and provides enough NAD+ for glycolysis, thus making astrocytes more resistant 
to the action of stimuli causing neurodegeneration.   
Therefore, we propose that expression of CD38 in neuronal and glial cells: 1) is regulated 
under (patho)physiological conditions; 2) is associated with various signal transduction 
pathways (i.e. GluR in neurons and Cx43 in astrocytes) whose activity is important for 
molecular pathogenesis of neurodegeneration; 3) reflects – specifically or non-specifically – 
mitochondrial dysfunction; 4) could be considered as a target for pharmacological correction 
of neurodegeneration. Deciphering of CD38-associated molecules/events in neuronal and 
glial populations would give us new biomarkers for diagnostics of neurodegeneration, 
while pharmacological manipulation of ADP-ribosyl cyclase activity in brain cells would 
provide new therapeutic opportunities for the treatment of neurodegenerative disorders.  
5. Modulation of NAD
+
 metabolism in glial cells as therapeutic approach in 
neurodegeneration 
Manipulating the neuron-glial cell interactions associated with changes in NAD+ levels 
represent one of the promising approaches to treatment of Alzheimer’s disease (Braidy et al., 
2008; Henricksen & Federoff, 2004). Pharmacological manipulation may be targeted to the 
modulation of intracellular NAD+ metabolism with substances affecting activity of NAD+-
synthesizing and NAD+-converting enzymes, modulators of NAD+-dependent enzymes (i.e. 
sirtuins, glycolytic enzymes), regulators of tryptophan kynurenine metabolism, substrates of 
NAD+ synthetic pathways, ligands and regulators of CD38 expression and activity, 
modulators of NAD+ and cyclic ADP-ribose transport across the membrane (i.e. Cx43). 
Metabolism of NAD+ could be efficiently regulated by inhibitors of mono(ADP-ribosyl) 
transferase and poly-ADP-ribosyl polymerase activities. Pharmacological interventions 
aimed at inhibiting PARP activity have been shown to be efficient in prevention of PARP-
mediated death of neurons and astrocytes (Ying, et al., 2002). Several studies have suggested 
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the therapeutic potential of sirtuins (NAD+-dependent histone deacetylases consuming 
NAD+) for Alzheimer’s disease (Anekonda & Reddy, 2006). Inhibitors of kynurenine  
3-hydroxylase can reduce the production of neurotoxic metabolites (Khan et al., 2007). It was 
reported that decreases in ǃ-amyloid content in the brain can be achieved by governing 
cellular sirtuin activity (Qin et al., 2006). Improvement of cognitive functions was detected 
after treatment with oral stabilized NADH (Demarin et al., 2004), probably, due to ability of 
NADH to enter into astrocyets and block PARP-mediated astrocyte death (Zhu et al., 2005). 
However, efficacy of NADH to correction of cognitive dysfunction in dementia remains to 
be ambiguos (Rainer et al., 2000). Recently, CD38 was suggested as a new target for 
dementias including Alzheimer’s disease (Chini et al., 2007). It is interesting enough that 
NAD+ (and, probably, NADH) can be transported across the plasma membranes of 
astrocytes through connexin hemichannels (Verderio, et al., 2001) or purinergic receptors 
(Lu et al., 2007), thus suggesting new approach to manipulating its intracellular 
concentrations and metabolism.   
Overexpression of NMNAT results in suppression of Wallerian degeneration in neurons, 
however, in Cd38-/- cells with higher levels of intracellular NAD+ no difference in the axon 
degeneration patterns were registered.  In general, increased NAD+ synthesis is responsible 
for axonal protection (Yan et al., 2010). In vitro NNMT expression significantly decreased 
cell death which correlated with increased intracellular ATP content, ATP: ADP ratio, 
Complex I activity and a reduction in the degradation of the NDUFS3 subunit of Complex I. 
These effects were replicated by incubation of cells with 1-methylnicotinamide. In the 
context of pathogenesis of Parkinson’s disease, it is important that both NNMT expression 
and 1-methylnicotinamide protected SH-SY5Y cells from the toxicity of the Complex I 
inhibitors MPP+ and rotenone by reversing their effects upon ATP synthesis, ATP:ADP 
ratio, Complex I activity and the NDUFS3 subunit (Parsons et al., 2011). Overexpression of 
SIRT1 or its activation in neuronal and glial cells with resveratrol has been shown to protect 
the brain tissue from degeneration in Alzheimer’s disease and Huntington’s disease, and 
calorie restriction able to modulate SIRT activity is neuroprotective against Parkinson’s 
disease and Alzheimer’s disease (Outeiro et al., 2008). Modulation of TRPM channels which 
are abundantly expressed in the brain has neuroprotective activity in Parkinson’s disease 
and Alzheimer’s disease (Yamamoto et al., 2007). Protection of neurons from glutamate and 
ǃ-amyloid toxicity was achieved by preloading neurons with creatine (Brewer & Wallimann, 
2000) or by pyruvate (Massieu et al., 2001). The latter as well as another tricarboxilic acid 
cycle substrate – ǂ-ketoglutarate - were also potent in preventing death of neurons and 
astrocytes caused by intracellular NAD+ depletion (Ying, et al., 2002).  
Experimental pharmacological intervention in the cADPR-signaling pathway are usually 
restricted to two targets, the cADPR-binding protein and the ADP-ribosyl cyclase (Guse, 
2000). The agents used for such properties are: a) cADP-ribose and its analogues; b) 
modulators of ryanodine receptors activity such as caffeine, ryanodine, procaine, ruthenium 
red; c) ligands of FKBP. The usefulness of cADP-ribose as a pharmacological tool is limited 
by its rapid hydrolysis, therefore various cADPR analogues have been synthesized.  
Among all inhibitors of NAD+-consuming enzymes, nicotinamide attracts the biggest 
interest. Nicotinamide has several cellular functions in CNS and serves as an anxiolytic, 
increases brain choline concentrations and is endogenous ligand of benzodiazepine 
receptors (Maiese & Chong, 2003). Neuroprotective action of nicotinamide has been 
reported in neurons at oxidative stress even it may be attributed to changes in glycolysis, 
apoptotic machinery, MAP kinase activity etc. rather than inhibition of NAD+ 
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glycohydrolases. Age-dependent susceptibility of glial cells to the action of nicotinamide 
analogs has been reported (Krum, 1995). 6-aminonicotinamide as niacin antagonist produces 
neurotoxic activity by inducing inflammatory response of astroglial and microglial cells 
(Penkowa et al., 2003). But using of inhibitors  of NAD+ hydrolysis may have even 
unfavorable results: partial inhibition of poly-ADP-ribosylation with 5-iodo-6-amino-1,2-
benzopyrone preserves NAD+ and improves functional outcome after traumatic brain 
injury, whereas more complete inhibition impairs spatial memory acquisition independent 
of injury (Satchell et al., 2003). Therefore, cytoprotection with inhibitors of NAD+-consuming 
enzymes might be concentration specific. We found that nicotinamide (500 mg/kg) reduced 
expression of CD38 in the brain cortex in the model of ischemia-induced acute 
neurodegeneration in adult rats in vivo and potentiate neurological dysfunction caused by 
ischemia, thereby further confirming ambiguity of nicotinamide action on neuronal and 
glial cells. 
Retinoic acid (RA) is a potent inducer of CD38 in peripheral blood cells, and recently it 
was suggested that this compound can be used to ‘rescue’ cells exhibiting low CD38 
synthesis and hence might be a novel therapeutic strategy in treatment of autism 
associated with impaired CD38 expression in neurosecretory cells (Ebstein et al., 2011). 
Cultured astrocytes express the key enzyme mRNAs of retinoic acid biosynthesis and 
actively produce retinoic acid acting at RA receptors (RAR). Synthesis of retinoic acid in 
astrocytes is provided by retinal dehydrogenase and alcohol dehydrogenase (Wagner et 
al., 2002). It was shown that blockage of retinoic acid signaling by the pan-RAR antagonist 
prevented glia-induced neuron formation by noncommitted stem cells, thus suggesting a 
role for retinoic acid in astroglia-induced neuronal differentiation (Kornyei et al., 2007). 
Retinoids control expression of wide spectrum of genes in neuronal and glial cells (Lane & 
Bailey, 2005). 
We tested effect of all-trans retinoic acid in vivo (20 mg/kg with ethanol to suppress 
endogenous synthesis of retinoic acid) in rats with experimental model of perinatal 
ischemic-hypoxic acute neurodegeneration. We found that suppression of endogenous 
synthesis of retinoic acid with ethanol reduced expression of CD38 in the cortex, while 
retinoic acid itself partially restored the level of CD38 (Salmina et al., 2009b).  
Retinoid and retinoid-associated signaling plays an essential role in normal 
neurodevelopment and appears to remain active in the adult CNS. Molecular factors 
involved in RA-mediated responses become up-regulated in the adult CNS as a 
consequence of injury or degeneration. Our data and recent findings of R. Ebstein et al. 
(Ebstein, et al., 2011) suggest that intervention that modulates RA-regulated CD38 may have 
therapeutic potential in CNS disorders.  It is interesting that a prolonged regime of vitamin 
A deprivation in adult rats has been shown to cause a deposition of ǃ-amyloid peptide in 
the forebrain, RA could regulate the expression of the tau protein, and in particular the level 
of phosphorylated forms of tau, as suggested by in vitro observations, vitamin A, as well as 
ǃ-carotene and coenzyme Q10, have also been shown to dose-dependently inhibit the 
formation of ǂ-synuclein fibrils in vitro, RA reduces the effect of ǃ-amyloid, and thus inhibits 
the neurotoxic effect of activated microglia, by suppressing the production of these cytotoxic 
molecules (Malaspina & Michael Titus, 2008). Retinoid receptors are involved in the 
regulation of brain functions, and retinoic acid signaling defects may contribute to 
pathologies such as Parkinson's disease (Krezel et al., 1998). Whether or not these events are 
associated with NAD+-converting activity of CD38 in neuronal and astroglial cells remains 
to be elucidated. 
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6. Concluding remarks and outstanding questions for further investigation 
So far, several hypotheses have been suggested to explain pathogenesis of acute and chronic 
neurodegenration. Almost all of the proposed mechanisms include processes considered as 
gliopathy (Maragakis & Rothstein, 2006; Verkhratsky, 2010). Different molecules mark 
gliopathological changes, and CD38 expressed in astroglial cells should be considered as 
one of the markers of neuron-astrocyte metabolic coupling. Neuron-glia communication is 
responsible for establishment of vicious circles in the pathogenesis of neurodegeneration, 
therefore deciphering new molecular mechanisms of intercellular communication will 
provide us with new diagnostic and therapeutic strategies. To achieve this goal in the 
context of NAD+-controlled neuronal-astroglial coupling, the following questions should be 
addressed: 
1. Which glial- and neuronal-derived factors can affect NAD+ metabolism in acute and 
chronic neurodegeneration? What is an integrative scheme for NAD+ homeostatic 
mechanisms in neurons and astrocytes? 
2. What is the role for CD38-Cx43 interactions in initiation and progression of 
mitochondrial dysfunction in neurodegeneration?  
3. Which molecular mechanisms coupled to NAD+ homeostasis in brain cells are involved 
in axonal degeneration and neuronal repair?  
4. Which new biomarkers could be developed for early diagnostics of astroglial 
dysfunction in neurodegeneration? Which molecular targets in neurons and glial cells 
could be efficiently used for the appropriate treatment of neurodegeneration? 
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